Condition: Primary Central Nervous System Lymphoma · Secondary Central Nervous System Lymphoma · Relapsed Cancer · Sponsor: Baptist Health South Florida
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.
This description comes directly from the study's public registry record.
Yuliya Linhares, M.D. · (786) 596-2000 · YuliyaL@baptisthealth.net
Allison Miller · (786) 527-8519 · Allison.Miller@baptisthealth.net
Always discuss trial participation with your own doctor first.
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05681195